Cargando…
Deletion of 18q is a strong and independent prognostic feature in prostate cancer
Deletion of 18q recurrently occurs in prostate cancer. To evaluate its clinical relevance, dual labeling fluorescence in-situ hybridization (FISH) using probes for 18q21 and centromere 18 was performed on a prostate cancer tissue microarray (TMA). An 18q deletion was found in 517 of 6,881 successful...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349918/ https://www.ncbi.nlm.nih.gov/pubmed/27861151 http://dx.doi.org/10.18632/oncotarget.13404 |
_version_ | 1782514559350734848 |
---|---|
author | Kluth, Martina Graunke, Maximilian Möller-Koop, Christina Hube-Magg, Claudia Minner, Sarah Michl, Uwe Graefen, Markus Huland, Hartwig Pompe, Raisa Jacobsen, Frank Hinsch, Andrea Wittmer, Corinna Lebok, Patrick Steurer, Stefan Büscheck, Franziska Clauditz, Till Wilczak, Waldemar Sauter, Guido Schlomm, Thorsten Simon, Ronald |
author_facet | Kluth, Martina Graunke, Maximilian Möller-Koop, Christina Hube-Magg, Claudia Minner, Sarah Michl, Uwe Graefen, Markus Huland, Hartwig Pompe, Raisa Jacobsen, Frank Hinsch, Andrea Wittmer, Corinna Lebok, Patrick Steurer, Stefan Büscheck, Franziska Clauditz, Till Wilczak, Waldemar Sauter, Guido Schlomm, Thorsten Simon, Ronald |
author_sort | Kluth, Martina |
collection | PubMed |
description | Deletion of 18q recurrently occurs in prostate cancer. To evaluate its clinical relevance, dual labeling fluorescence in-situ hybridization (FISH) using probes for 18q21 and centromere 18 was performed on a prostate cancer tissue microarray (TMA). An 18q deletion was found in 517 of 6,881 successfully analyzed cancers (7.5%). 18q deletion was linked to unfavorable tumor phenotype. An 18q deletion was seen in 6.4% of 4,360 pT2, 8.0% of 1,559 pT3a and 11.8% of 930 pT3b-pT4 cancers (P < 0.0001). Deletions of 18q were detected in 6.9% of 1,636 Gleason ≤ 3 + 3, 6.8% of 3,804 Gleason 3 + 4, 10.1% of 1,058 Gleason 4+3, and 9.9% of 344 Gleason ≥ 4 + 4 tumors (P = 0.0013). Deletions of 18q were slightly more frequent in ERG-fusion negative (8.2%) than in ERG-fusion positive cancers (6.4%, P = 0.0063). 18q deletions were also linked to biochemical recurrence (BCR, P < 0.0001). This was independent from established pre- and postoperative prognostic factors (P ≤ 0.0004). In summary, the results of our study identify 18q deletion as an independent prognostic parameter in prostate cancer. As it is easy to measure, 18q deletion may be a suitable component for multiparametric molecular prostate cancer prognosis tests. |
format | Online Article Text |
id | pubmed-5349918 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53499182017-04-06 Deletion of 18q is a strong and independent prognostic feature in prostate cancer Kluth, Martina Graunke, Maximilian Möller-Koop, Christina Hube-Magg, Claudia Minner, Sarah Michl, Uwe Graefen, Markus Huland, Hartwig Pompe, Raisa Jacobsen, Frank Hinsch, Andrea Wittmer, Corinna Lebok, Patrick Steurer, Stefan Büscheck, Franziska Clauditz, Till Wilczak, Waldemar Sauter, Guido Schlomm, Thorsten Simon, Ronald Oncotarget Research Paper Deletion of 18q recurrently occurs in prostate cancer. To evaluate its clinical relevance, dual labeling fluorescence in-situ hybridization (FISH) using probes for 18q21 and centromere 18 was performed on a prostate cancer tissue microarray (TMA). An 18q deletion was found in 517 of 6,881 successfully analyzed cancers (7.5%). 18q deletion was linked to unfavorable tumor phenotype. An 18q deletion was seen in 6.4% of 4,360 pT2, 8.0% of 1,559 pT3a and 11.8% of 930 pT3b-pT4 cancers (P < 0.0001). Deletions of 18q were detected in 6.9% of 1,636 Gleason ≤ 3 + 3, 6.8% of 3,804 Gleason 3 + 4, 10.1% of 1,058 Gleason 4+3, and 9.9% of 344 Gleason ≥ 4 + 4 tumors (P = 0.0013). Deletions of 18q were slightly more frequent in ERG-fusion negative (8.2%) than in ERG-fusion positive cancers (6.4%, P = 0.0063). 18q deletions were also linked to biochemical recurrence (BCR, P < 0.0001). This was independent from established pre- and postoperative prognostic factors (P ≤ 0.0004). In summary, the results of our study identify 18q deletion as an independent prognostic parameter in prostate cancer. As it is easy to measure, 18q deletion may be a suitable component for multiparametric molecular prostate cancer prognosis tests. Impact Journals LLC 2016-11-16 /pmc/articles/PMC5349918/ /pubmed/27861151 http://dx.doi.org/10.18632/oncotarget.13404 Text en Copyright: © 2016 Kluth et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Kluth, Martina Graunke, Maximilian Möller-Koop, Christina Hube-Magg, Claudia Minner, Sarah Michl, Uwe Graefen, Markus Huland, Hartwig Pompe, Raisa Jacobsen, Frank Hinsch, Andrea Wittmer, Corinna Lebok, Patrick Steurer, Stefan Büscheck, Franziska Clauditz, Till Wilczak, Waldemar Sauter, Guido Schlomm, Thorsten Simon, Ronald Deletion of 18q is a strong and independent prognostic feature in prostate cancer |
title | Deletion of 18q is a strong and independent prognostic feature in prostate cancer |
title_full | Deletion of 18q is a strong and independent prognostic feature in prostate cancer |
title_fullStr | Deletion of 18q is a strong and independent prognostic feature in prostate cancer |
title_full_unstemmed | Deletion of 18q is a strong and independent prognostic feature in prostate cancer |
title_short | Deletion of 18q is a strong and independent prognostic feature in prostate cancer |
title_sort | deletion of 18q is a strong and independent prognostic feature in prostate cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349918/ https://www.ncbi.nlm.nih.gov/pubmed/27861151 http://dx.doi.org/10.18632/oncotarget.13404 |
work_keys_str_mv | AT kluthmartina deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT graunkemaximilian deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT mollerkoopchristina deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT hubemaggclaudia deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT minnersarah deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT michluwe deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT graefenmarkus deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT hulandhartwig deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT pomperaisa deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT jacobsenfrank deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT hinschandrea deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT wittmercorinna deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT lebokpatrick deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT steurerstefan deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT buscheckfranziska deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT clauditztill deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT wilczakwaldemar deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT sauterguido deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT schlommthorsten deletionof18qisastrongandindependentprognosticfeatureinprostatecancer AT simonronald deletionof18qisastrongandindependentprognosticfeatureinprostatecancer |